Effect of Statins on Asthma Control in Smokers With Asthma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00463827|
Recruitment Status : Completed
First Posted : April 20, 2007
Last Update Posted : March 28, 2017
Asthma is a chronic inflammatory condition of the lungs.
There is evidence that cigarette smoking can make asthma symptoms worse and that smokers with asthma do not respond as well to standard therapies as non-smokers.
Statins are drugs which are already used to lower cholesterol. They have also been shown to have some anti-inflammatory properties.
In this trial the investigators will give a randomised group of smokers Atorvastatin and the remaining group a placebo or blank tablet. The investigators will then monitor patients' responses in terms of peak flow data, symptom diaries, questionnaires and breathing tests.
|Condition or disease||Intervention/treatment||Phase|
|Asthma COPD Smoking||Drug: Atorvastatin Drug: atorvastatin Drug: matched placebo||Phase 2|
Despite several studies, which have shown that smokers with asthma have more severe symptoms, accelerated decline in lung function and diminished response to treatment with inhaled and oral corticosteroids, more than 25% of asthmatics continue to smoke. Smoking cessation advice is often ineffective.
Statins are used as cholesterol lowering agents, however, there is now also evidence that they have additional anti-inflammatory effects which may be useful in treatment of smokers with asthma.
This is a randomised placebo controlled double-blind parallel group study.
Following screening to assess suitability for the study, patients will be randomised to treatment with either Atorvastatin 40mg or placebo (blank tablet)for 8 weeks.
After 4 weeks of treatment, all patients will be commenced on a low dose inhaled corticosteroid for the remainder of the study to assess whether treatment with statins can overcome steroid resistance in smokers with asthma.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||71 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Effect of Statins on Asthma Control and Airway Inflammation in Smokers With Asthma: a Randomised Controlled Double-blind Parallel Group Study|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||June 2009|
|Actual Study Completion Date :||June 2009|
Active Comparator: 2
Placebo Comparator: placebo
Drug: matched placebo
- Change in peak flow data [ Time Frame: 4 weeks ]
- sputum cell counts [ Time Frame: 4 weeks and 8 weeks ]
- spirometry [ Time Frame: 4 weeks and 8 weeks ]
- airway responsiveness to methacholine [ Time Frame: 4 weeks and 8 weeks ]
- symptom scores [ Time Frame: 4 weeks and 8 weeks ]
- Exhaled and alveolar NO [ Time Frame: 4 weeks and 8 weeks ]
- Exacerbation rates [ Time Frame: 4 and 8 weeks ]
- immunological tests in blood [ Time Frame: 4 and 8 weeks ]
- ACQ score [ Time Frame: 4 and 8 weeks ]
- AQLQ score [ Time Frame: 4 and 8 weeks ]
- Safety issues [ Time Frame: 4 and 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00463827
|Gartnavel General Hospital|
|Glasgow, United Kingdom, G12 0YN|
|Principal Investigator:||Neil Thomson, FRCP||University of Glasgow|